<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578341</url>
  </required_header>
  <id_info>
    <org_study_id>212250-2320-10305-01-16</org_study_id>
    <nct_id>NCT03578341</nct_id>
  </id_info>
  <brief_title>Oral Colostrum and Its Effect on Immune System</brief_title>
  <official_title>Effect of Early Oral Colostrum Administration Versus Placebo on the Immune System in Premature Newborns Under 32 Weeks of Gestation: A Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to increase the serum immunological defenses of premature
      infants less then 32 weeks of gestation by administrating colostrum in the oropharyngeal
      mucosa versus placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prematurity is a public health problem because premature newborns have an immature immune
      system. Breast milk (colostrum) contains bioactive components that provide antimicrobial,
      anti-inflammatory, antioxidant, and immunomodulatory functions. These bioactive components
      are in higher concentrations in mothers' colostrum of premature babies. Because of the
      morbidities presented by premature infants, they remain fasting and lack the potential
      benefit provided by colostrum. When the colostrum is placed in the oropharyngeal mucosa, the
      immunocompetent cells stimulate the immune system, increasing the serum concentrations of
      immunoglobulins.

      Objectives: To determine the efficacy of early administration of colostrum in the
      oropharyngeal mucosa in preterm infants less than 32 weeks of gestation and its effect on the
      immune system by quantifying immunoglobulins in preterm infants born at the National
      Institute of Perinatology. .

      Methods / Design: 1 year, double blind randomized controlled clinical trial. The newborns
      included will be randomly assigned to one of the 2 groups: Group 1:, newborns receiving
      colostrum 0.3 mL every 4 hours in the oropharyngeal mucosa, for 3 days.

      Newborns from Block B will receive orally sterile water (placebo) 0.3 mL following the same
      protocol. Serum immunoglobulin A, M and G concentrations will be determined before the start
      of the study on day 0 of life and after 7 and 28 days of life. They will continue in time
      until 36 SDG or at discharge, whichever comes first.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Intervention Model Description: The Participants will be randomly and assigned to Group 1, or Group 2 . using a table of random numbers, generated by a computer. The Human Milk Bank Staff, will prepares the colostrum and water (placebo) doses in syringes in such a way that it is not detected that it contains each of them, . Group 1: Will receive 0.3 mL orally colostrum every 4 h during three days, Group 2: will receive 0.3 mL orally Sterile water. Serum immunoglobulins A, G and M concentration will be determined before de start the orally doses, day 7 and 28 days of life.he nurse in charge of the patient's care, administer the dose, a doctor will take the laboratory exams and another researcher will collect and analyze the data. The syringes will be covered, to prevent the patiente´s nurse from observing the contents.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Masking Description: The colostrum and placebo will be preparing by a Human Milk Bank person, who will be knowing the treatment of both 2nd and 1st group. Both colostrum and placebo, will be administrating by nursing staff in syringes in such a way that it is not detected that it contains each of them. Neither the parents of the participants nor the researchers will be involved in the care or analysis of the data, until the end of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of serum Immunoglobulins</measure>
    <time_frame>From baseline to day 7</time_frame>
    <description>Quantification of immunoglobulins IgA, IgG and IgM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sepsis neonatal</measure>
    <time_frame>28 days of postnatal age</time_frame>
    <description>Frequency of neonatal sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotising Enterocolitis</measure>
    <time_frame>28 days of postnatal age</time_frame>
    <description>Frequency of neonatal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of serum Immunoglobulins</measure>
    <time_frame>From baseline to day 28</time_frame>
    <description>Quantification of immunoglobulins IgA, IgG and IgM</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Immune System Diseases</condition>
  <condition>Premature Infant Disease</condition>
  <condition>Immunoglobulin Deficiency</condition>
  <arm_group>
    <arm_group_label>Colostrum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1:(Colostrum): Preterm infants under 32 SDG will receive orally colostrum 0.3 mL every 4 h during three days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 2: (Placebo): Preterm newborns under 32 SDG who will receive orally sterile water 0.3 mL every 4 h during three days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Orally Colostrum</intervention_name>
    <description>Group 1, Will receive colostrum 0.3 mL every 4 hours in the oropharyngeal mucosa, for 3 days.</description>
    <arm_group_label>Colostrum</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NEWBORN 32 Gestational weeks

          -  Hospitalized in neonatal intensive care Unit

          -  Agreement signed by the legal representative

        Exclusion Criteria:

          -  Intraventricular haemorrhage II/IV grade

          -  Congenital sepsis (early sepsis)

          -  Congenital malformations

          -  Early transfusions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>36 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martha Morelos-Gonzalez, Chem</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diana M Soriano-Becerril, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge A Cardona-Pérez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Araceli Montoya-Estrada, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elsa Castro-Millán, Thec</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique Segura -Cervantes, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guadalupe del Carmen Estrada-Gutierrez</name>
      <address>
        <city>Miguel Hidalgo</city>
        <state>Ciudad DE México</state>
        <zip>11000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silvia Romero-Maldonado</name>
      <address>
        <city>Miguel Hidalgo</city>
        <state>Ciudad DE México</state>
        <zip>11000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes</investigator_affiliation>
    <investigator_full_name>Silvia Romero-Maldonado</investigator_full_name>
    <investigator_title>NEONATOLOGIST</investigator_title>
  </responsible_party>
  <keyword>Immunoglobulins A, G and M</keyword>
  <keyword>Neonatal Sepsis</keyword>
  <keyword>Human Milk</keyword>
  <keyword>Orally Colostrum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Infant, Premature, Diseases</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patients will be registered in a SPSS database</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>The Data will be available in 2019, after the protocol is finished, for a month</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

